Currently used clinical and pathologic parameters, such as intestinal perforation/obstruction, tumor size and tumor grade [4], molecular markers, such as mutations in KRAS and BRAF as well as chromosome and microsatellite instability (MSI) [5-10] cannot adequately assess relapse risk to guide the clinical adjuvant CTX after surgery [11, 12]. This evidence concerns the gene KRAS and neoplasm.